© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Latest Conference Articles
Postnatal Antibiotics for Maternal Indications May Heighten Childhood Asthma Risk
February 12th 2025
AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.
AAAAI 2025: Omalizumab Shows Favorable Outcomes Versus Oral Immunotherapy in Multi‐Food Allergy Treatment
February 12th 2025
In a randomized clinical trial, omalizumab achieved a 36% treatment success rate for multi-food allergy compared with 19% for oral immunotherapy.
Expert Perspectives 2024: Nonsteroidal Topicals for Atopic Dermatitis with Mona Shahriari, MD
December 12th 2024
The new nonsteroidal topical treatments for atopic dermatitis are targeted and modify the disease process, explains thought leader Shahriari in this year's video series.
Nonsteroidal Topical Treatments for Eczema: A Product Snapshot with Mona Shahriari, MD
November 6th 2024
They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.
Why is Atopic Dermatitis Prevalence Rising? Dermatologist Mona Shahriari, MD, Parses the Trends
October 22nd 2024
Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.
SECURE-T2D: Automated Insulin Delivery System Reduced A1c in Adults with Type 2 Diabetes
June 27th 2024
ADA 2024. Adults started on the Omnipod 5 AID system had an A1c reduction from 8.2% at baseline to 7.4% at 13 weeks, researchers report.
One-Quarter of Adults with Difficult-to-Control T2D have Hypercortisolism, According to New Data
June 26th 2024
ADA 2024. Adults using more antihypertensive medications had higher odds for hypercortisolism, according to new data from the CATALYST phase 4 study.
FLOW Trial: Semaglutide Lowers Risk for Major Kidney Disease, CV Events and Death Regardless of SGLT-2i Use
June 25th 2024
ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.
SURMOUNT-OSA: Tirzepatide Improves Sleep Apnea Symptoms, CV Outcomes in Adults with OSA and Obesity
June 24th 2024
ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.
Pemvidutide Preserves Lean Mass With Weight Loss of Nearly 16%: MOMENTUM Phase 2 Trial
June 24th 2024
ADA 2024. MOMENTUM trial findings presented at the ADA yesterday showed 78.1% of weight loss attributable to loss of fat vs lean mass in adults with overweight or obesity.